ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a large retrospective observational study of coronary orbital atherectomy were released at TCT Connect 2020. The presentation, authored […]
Coronary/Structural Heart
Foldax Named Cardiovascular Device Company of the Year by MedTech Outlook
SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that it has been selected as Company of the Year among 10 cardiovascular device company finalists by MedTech Outlook Magazine. Foldax was honored for its innovative Tria™ heart valve, the first biopolymer heart valve to receive FDA approval for a U.S. clinical trial. Foldax has reinvented every […]
GE Healthcare Receives FDA Clearance for Vivid Ultra Edition, AI-Powered Cardiovascular Ultrasound System Designed to Shorten Diagnostic Exam Time and Improve Measurement Consistency
CHICAGO–(BUSINESS WIRE)–GE Healthcare today announced U.S. FDA 510k clearance for its Ultra Edition package on Vivid1 cardiovascular ultrasound systems, which includes new features based on artificial intelligence (AI) that enable clinicians to acquire faster, more repeatable exams consistently. Methodical assessments of heart function are key in echocardiography but can be tedious […]
CARMAT is granted €13 million in national innovation funding to conduct the EFICAS study in France
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces that it has been granted €13 million in funding […]
LivaNova Presents New Data at European Association for Cardio-Thoracic Surgery Annual Meeting Demonstrating Benefits of Perceval Sutureless Valve
New PERSIST-AVR study results and SURE-AVR registry data analysis underscore utility of Perceval as a minimally invasive surgical approach for patients with aortic valve stenosis LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced new data from the Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study and […]
TCT Connect to Highlight How Impella Enables Improved Outcomes for High-Risk PCI, Cardiogenic Shock and Right Heart Failure Patients
DANVERS, Mass.–(BUSINESS WIRE)–The benefits of a more complete revascularization with Impella heart pumps in high-risk percutaneous coronary intervention (PCI) patients and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients will be highlighted at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. […]
NILEMDO® significantly lowers cholesterol in people with familial hypercholesterolaemia shows new analysis presented at EAS 2020
NILEMDO® (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers cholesterol and can be combined with other treatments to help lower cholesterol even further1 Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to […]
Elucid Bio’s vascuCAP enters IBM Imaging AI Marketplace
BOSTON–(BUSINESS WIRE)–Elucid Bioimaging Inc. (“Elucid Bio”) today announced that vascuCAP, Elucid Bio’s AI-enabled software for evaluating atherosclerotic plaque stability from CTA, has been added to the IBM Imaging AI Marketplace, an IBM Watson Health® solution. The IBM Imaging AI Marketplace provides streamlined access to meaningful AI technologies designed to support leaders […]
Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death Results Will Be Presented in Late Breaking Clinical Trial Session at AHA Scientific Sessions 2020 THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Oct. 8, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN), Cytokinetics, […]
CHF Solutions Announces Data Demonstrating Benefit of Aquadex Therapy for Treatment of Heart Failure and COVID-19
EDEN PRAIRIE, Minn., Oct. 07, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced data from a retrospective study and a case study supporting the benefit of Aquadex™ therapy in the treatment of heart […]



